Age-Related Macular Degeneration (AMD)
Age-related macular degeneration is a progressive disease of the macula, the central part of the retina responsible for sharp, detailed vision, and one of the leading causes of irreversible vision loss in people over fifty. It affects a very large and growing population worldwide, and for its early and intermediate dry stages there is, to date, no approved treatment beyond nutritional supplements and lifestyle measures, leaving a genuine unmet need.
Classification
AMD is clinically staged by the extent of retinal change:
- Early AMD: small drusen deposits, with limited impact on vision.
- Intermediate AMD: larger drusen and possible early vision changes; this is the principal focus of photobiomodulation research.
- Late or advanced AMD: significant vision loss, subdivided into a dry form (geographic atrophy) and a wet form (neovascular).
The unmet need
For early and intermediate dry AMD, management has long been limited to AREDS-type supplements and lifestyle advice, with no therapy that acts on the disease process itself. This gap is precisely what light-based therapy is being investigated to address.
How photobiomodulation is being studied
LM™ LLLT photobiomodulation acts on retinal cell metabolism through the mechanisms described in how photobiomodulation works: restoring mitochondrial function and ATP production in photoreceptors, increasing nitric-oxide signalling to reduce oxidative stress, and, with yellow wavelengths, inhibiting VEGF expression associated with abnormal blood-vessel growth.
Early clinical work has examined safety, tolerability and short-term efficacy of eye-light® photobiomodulation for dry AMD (Borrelli et al., 2024, Ophthalmology and Therapy), and reported choriocapillaris perfusion enhancement and outer retinal remodelling in intermediate AMD, with significant visual acuity improvement and drusen volume reduction at follow-up (Viggiano et al., 2025, Eye). A multicentric trial programme is underway to build on these findings. See clinical trials.
Regulatory status
The eye-light® device has obtained a CE (MDR) clearance covering the treatment of dry AMD, a significant milestone for photobiomodulation in posterior-segment care. Availability and cleared indications vary by region. For patients, see the AMD guide.
Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.